(RFL) Rafael Holdings, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RFL) Rafael Holdings, Inc. Complete Analysis Pack
Validate Every Claim with the Complete Sources File
This Rafael Holdings, Inc. SWOT Analysis gives a concise, structured view of the company’s strengths, weaknesses, opportunities, and threats to support research, strategy, or investing. The page already includes a real preview/sample of the report so you can judge format and depth before buying—purchase the full version to download the complete, ready-to-use analysis.
Strengths
2 operating divisions
In FY2025, Rafael Holdings, Inc. operated 2 businesses: Pharmaceuticals and Real Estate. That gives the Company exposure to both drug-development upside and property cash flow. The split also helps reduce dependence on a single revenue stream, which can smooth results when one segment is weak.
CPI-613 in 2 Phase III registrational studies
Rafael Holdings, Inc. has CPI-613 devimistat in two Phase III registrational studies, a rare late-stage position for a small-cap biotech. The trials target advanced pancreatic cancer and relapsed or refractory acute myeloid leukemia, giving the asset clear clinical and regulatory readouts. Late-stage status lifts validation potential and can support a higher probability-adjusted value than earlier pipeline programs.
800-space public parking facility
Rafael Holdings, Inc.'s real estate complex includes an integrated 800-space public parking facility, giving it a sizable, monetizable asset tied directly to the office property. That scale can support tenant convenience, visitor access, and steady ancillary income beyond base rent. In a market where parking supply is often constrained, 800 spaces also add flexibility for office users and events.
Early-stage and clinical pharma investments
Rafael Holdings, Inc. has strategic stakes in early-stage and clinical pharma companies, so its upside is not tied only to its lead program. This gives it exposure to multiple pipeline shots on goal and several possible value events, from data readouts to partnering deals. For investors, that means more optionality, but also higher biotech risk and trial volatility.
- Multiple pipeline assets can drive new catalysts
- Value can come before full commercialization
- Reduces dependence on one lead program
US and Israel asset base
Rafael Holdings’ commercial real estate base spans the United States and Israel, giving it two markets instead of one. That cross-border footprint can open more tenant and financing options while spreading country-specific risk. It also adds geographic diversification, which can help soften local shocks in either market.
- Assets in both the United States and Israel
- Broader market access and optionality
- Better geographic risk spread
Rafael’s FY2025 Edge: Dual-Track Growth and Late-Stage Cancer Drug Momentum
Rafael Holdings, Inc. showed two core strengths in FY2025: a dual-track model in Pharmaceuticals and Real Estate, plus late-stage CPI-613 devimistat in two Phase III registrational studies. It also held an 800-space public parking asset and commercial real estate in the United States and Israel, adding cash-flow and geographic spread.
| Strength | FY2025 data |
|---|---|
| Business mix | 2 segments |
| Lead asset | 2 Phase III studies |
| Parking asset | 800 spaces |
| Geography | U.S. and Israel |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Rafael Holdings, Inc.’s business strategy
Editable Excel File
Provides a concise Rafael Holdings, Inc. SWOT snapshot to quickly clarify strategic risks and opportunities.
Reference Sources
Provides a concise, traceable list of primary industry reports, government data, and benchmarks to speed due diligence and validate key assumptions.
Weaknesses
1 lead drug candidate
Rafael Holdings, Inc. leans heavily on one main drug story: CPI-613/devimistat. That single-program focus creates a clear single-point-of-failure risk, so any trial delay, safety issue, or weak efficacy data could hit valuation fast. With little pipeline diversification, the stock’s upside is tied to one asset’s outcome.
No approved pharma product
Rafael Holdings, Inc. still has no approved pharma product, so the segment has not generated commercial drug sales. CPI-613 remains under clinical evaluation, which keeps revenue from this asset at $0 and leaves the path to approval long and uncertain. That delay also pushes out any near-term payoff from a drug launch.
Office-property concentration
Rafael Holdings, Inc.’s real estate segment is concentrated in one office complex, so one asset drives most of the segment’s risk. That leaves Rafael Holdings, Inc. exposed to localized vacancy, slower lease-up, and tenant rollover shocks if demand weakens. With limited portfolio breadth, one soft quarter can hit occupancy and cash flow harder than in a diversified REIT.
Commercial office exposure
Rafael Holdings, Inc. still has office real estate in its property mix, and that is a weak spot as U.S. office vacancy stayed near 19.8% in 2025, with landlords facing softer demand and more lease giveaways. Leasing can swing fast when tenants renew, shrink space, or leave, and parking income usually drops when office traffic falls.
- Office demand stayed weak in 2025.
- Renewals and downsizing can hurt rent rolls.
- Parking revenue moves with foot traffic.
Capital-intensive development model
Rafael Holdings, Inc. has a capital-heavy model: clinical trials need steady cash, and its real estate assets also need ongoing upkeep. If funding gets tighter, the Company can be forced to slow research or delay property spending, which hurts flexibility.
That risk is real for a small-cap Company that must keep raising money to fund both pipelines and operations. The more capital it needs, the more exposed it is to higher rates, weaker equity markets, and dilution.
- Clinical trials need recurring cash.
- Property upkeep also drains capital.
- Tight markets can limit funding.
- More funding can mean dilution.
Rafael’s One-Drug Bet and Weak Office Market Keep Risks High
Rafael Holdings, Inc. remains weak because it still depends on one unproven drug, CPI-613/devimistat, while its office assets face a soft market: U.S. office vacancy was about 19.8% in 2025. That mix keeps revenue uncertain, raises dilution risk, and limits near-term cash flow.
| Weakness | Data point |
|---|---|
| Drug concentration | 1 lead asset |
| Office market risk | 19.8% vacancy in 2025 |
| Commercial revenue | $0 from approved drug sales |
Get Your Copy
Rafael Holdings, Inc. Reference Sources
This is the actual SWOT analysis document you'll receive upon purchase—no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.
Opportunities
2 Phase III readouts
Rafael Holdings, Inc. has two registrational Phase III readouts for CPI-613, one in pancreatic cancer and one in AML, as near-term catalysts. Positive data from either study could shift the Company’s profile from development-stage to a clearer regulatory story. If both trials read out well, the case for approval and future revenue rises fast.
Pancreatic cancer market
Advanced pancreatic cancer is still a high-need field, with about 67,400 new U.S. cases and about 52,000 deaths expected in 2025. A therapy that improves survival or response in this hard-to-treat group could win strong clinical use and pricing power. That makes pancreatic cancer a meaningful commercial opening for Rafael Holdings, Inc.
AML treatment opportunity
Relapsed or refractory acute myeloid leukemia remains a high-unmet-need market, with 5-year survival still under 10% for many patients and about 20,800 U.S. AML diagnoses expected in 2024. CPI-613 in this late-line setting can support a strong need-based story. If clinical data hold, Rafael Holdings, Inc. could add a second major oncology lane beyond its current focus.
Licensing and partnerships
CPI-613 is Rafael Holdings, Inc.'s late-stage oncology asset, and if data stay supportive, licensing or regional partnerships could help move it into development or commercialization faster. In biopharma, Phase 3 deals often shift trial spend and launch risk to a partner, so Rafael could cut funding needs while keeping upside.
- Late-stage data can attract partners
- Regional rights can fund progress
- Shared costs reduce dilution risk
Real estate monetization
Rafael Holdings, Inc.’s office complex and 800-space parking facility can keep producing steady operating income, and better leasing or higher use should lift property-level returns. Real estate cash flow can also fund broader corporate goals, giving the company a non-dilutive source of support while it pursues biotech and other investments.
- Stable rent and parking income
- Higher occupancy can boost returns
- Cash flow can support strategy
Rafael’s CPI-613 Could Unlock Major Value
Rafael Holdings, Inc.’s biggest opportunity is CPI-613: two Phase III readouts could unlock value, with about 67,400 U.S. pancreatic cancer cases expected in 2025 and about 20,800 AML diagnoses expected in 2024. Positive data could support approval talks, partnerships, and lower funding needs. Its office and parking assets also add steady cash flow.
| Opportunity | Key data |
|---|---|
| CPI-613 Phase III | 2 readouts |
| Pancreatic cancer | 67,400 U.S. cases, 2025 |
| AML market | 20,800 U.S. diagnoses, 2024 |
| Real estate cash flow | 800-space parking facility |
Threats
Phase III trial failure risk
CPI-613’s pivotal risk is high: oncology Phase III trials fail more than 50% of the time, and a miss in pancreatic cancer or AML would weaken Rafael Holdings, Inc.'s main growth case. Clinical data can swing fast, so one negative readout could cut both valuation and partnership appeal.
Regulatory uncertainty
Regulatory uncertainty remains a real threat for Rafael Holdings, Inc. Even strong trial data do not guarantee approval, because regulators can ask for more analyses, extra patients, or longer follow-up before clearing a product. The FDA’s standard review clocks are 6 months for priority review and 10 months for standard review, but requests for more data can push launch far beyond that and raise cash burn.
Strong oncology competition
Pancreatic cancer and AML are crowded fields, with U.S. 5-year survival still only about 13% for pancreatic cancer and about 31% for AML, which keeps drug makers pushing hard for better results. If rival therapies show stronger efficacy or safer profiles, CPI-613 could lose share even if it reaches market. That competition can shrink pricing power, adoption, and long-term revenue for Rafael Holdings, Inc.
Office market pressure
Commercial office real estate remains under pressure: U.S. office vacancy hit 19.8% in Q4 2025, and asking rents in weaker submarkets kept slipping. That can cut leasing income and push down asset values, so Rafael Holdings, Inc.'s office-heavy base stays exposed to a cycle with slower demand and higher concessions.
- Vacancy stays near 20%.
- Rent growth remains weak.
- Lower NOI can hit valuation.
Financing and dilution risk
Rafael Holdings, Inc. faces financing and dilution risk because ongoing R&D and property spending can outstrip internal cash flow. If it raises money with new shares, existing holders own a smaller slice of the business. That risk rises when capital markets are tight, since equity funding can become more expensive and less available.
- More R&D can pressure cash.
- Equity raises can dilute holders.
- Tight markets raise funding risk.
Rafael Faces Trial, FDA, and Competition Risks
Rafael Holdings, Inc. faces three main threats: CPI-613 trial failure, FDA delays, and fierce oncology competition. A Phase III miss can erase most upside, while longer review cycles can raise cash burn and slow launch timing.
| Threat | Key data |
|---|---|
| Office real estate | U.S. vacancy 19.8% in Q4 2025 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.